Journal Article

Plasma DNA and metastatic castration-resistant prostate cancer: The odyssey to a clinical biomarker test

Cancer Discovery (2018) 8(4) 392-394
DOI: 10.1158/2159-8290.CD-18-0124
7Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption of TP53 or BRCA2 or ATM detected in plasma have significantly worse outcomes on novel AR targeting.

Cite

CITATION STYLE

APA

Jayaram, A., Wetterskog, D., & Attard, G. (2018). Plasma DNA and metastatic castration-resistant prostate cancer: The odyssey to a clinical biomarker test. Cancer Discovery, 8(4), 392–394. https://doi.org/10.1158/2159-8290.CD-18-0124

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free